New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients wit... (taneous conversion to monotherapy from t...)

HOME >> MEDICINE >> TECHNOLOGY

New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy

Date:10/15/2007

taneous conversion to monotherapy from two or more concomitant AEDs.

Lamictal is also approved for maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adult patients treated for acute mood episodes with standard therapy. The effectiveness of Lamictal in the acute treatment of mood episodes has not been established.

Serious rashes requiring hospitalization and discontinuation of treatment have been reported in association with the use of Lamictal. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8 percent (8 per 1000) in pediatric patients under the age of 16 years receiving Lamictal as adjunctive therapy for epilepsy, and 0.3 percent (3 per 1000) in adults on adjunctive therapy for epilepsy. In clinical trials of bipolar and other mood disorders, the rate of serious rash was 0.08 percent of adult patients who received Lamictal as initial monotherapy and 0.13 percent of adult patients who received Lamictal as adjunctive therapy. In a prospectively followed cohort of 1,983 pediatric patients taking adjunctive Lamictal, there was one rash-related death.

About GlaxoSmithKline

GlaxoSmithKline (NYSE: GSK), with U.S. operations in Philadelphia, P.A. and Research Triangle Park, N.C., is one of the world's leading research-based pharmaceutical and healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. More information on GlaxoSmithKline is available at the company's Web site at http://www.gsk.com.

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression

Post Your Comments:

(Date:12/17/2009)... RALEIGH, N.C., Dec. 17 Pharmaceutical Institute ... from GeneEd, Inc., a company specializing in life ... advanced e-courses, help expand Pharmaceutical Institute,s already extensive ... Institute is a leading provider of specialized training ... a subsidiary of Campbell Alliance. Financial terms ...

(Date:12/17/2009)... PHOENIX, Dec. 17 The Make-A-Wish Foundation ... million donation from the LATISSE ® ... sponsored by Allergan, Inc. ,, Based on the ... a wish come true, the campaign launched earlier ... the Make-A-Wish Foundation by leveraging the excitement around ...

(Date:12/16/2009)... Cell Therapeutics, Inc. (CTI) (Nasdaq ... February 10, 2010 the U.S. Food and ... will review the New Drug Application (NDA) ... aggressive non-Hodgkin,s lymphoma (NHL). ODAC is an ... concerning the efficacy and safety of marketed ...

[0] Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc.[0] The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign [0] Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010

... at least 45% additional,reduction in patients' LDL-cholesterol ... May 17, 2007 /PRNewswire-FirstCall/ -- Isis,Pharmaceuticals, Inc. ... clinical trial of ISIS 301012 in patients ... which were,presented in March at the of ...

... 17, 2007 - BioLineRx Ltd. (TASE:,BLRX), Israel's ... containing data from its successfully completed,phase I ... GABA-enhanced,antipsychotic for the treatment of schizophrenia, have ... scientific,conferences. The data will be presented at ...

Other Medicine Technology:Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 2 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 3 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 4 Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients 5 BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 2 BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 3

Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences

(Date:12/17/2009)... Helped, Healed, and Preserved Good Health , ... ... Association (IHRSA) announced today that as part of its Campaign for ... abilities to make 2010 the year we unite in a national ... daily exercise is highly valued and widely practiced. IHRSA is inviting ...

(Date:12/17/2009)... , , THURSDAY, Dec. 17 (HealthDay News) -- Among teenage ... least one of three common sexually transmitted infections -- ... becoming sexually active, a new study has found. , ... also found that it was common for these patients ... within four to six months after treatment of the ...

(Date:12/17/2009)... of Science in Human Resource Development Degree Online , ... ... -- Open enrollment has begun for Villanova’s newly online ... professionals whose busy schedules can’t accommodate a campus-based program. With ... online in March 2010, location is no longer a barrier ...

(Date:12/17/2009)... SAN DIEGO, Dec. 17 Neurocrine Biosciences, Inc. ... entered into a privately negotiated transaction to sell an ... to affiliates of Venrock at a price of $2.09 ... approximately $10 million. Neurocrine expects the financing to close ... closing conditions. ,, A shelf registration statement ...

(Date:12/17/2009)... Procedure Provides Efficient Mechanism to Pursue Approval ... Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... it has initiated the regulatory approval process ... under the Decentralized Procedure (DCP). The DCP ... company to simultaneously pursue regulatory approval for ...

Breaking Medicine News(10 mins):Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 2 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 3 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 4 Health News:IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active 5 Health News:STDs Common Among Sexually Active Teen Girls in Cities 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2 Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 2 Health News:Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million 3 Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 2 Health News:Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe 3

[0] IHRSA's Campaign for a Healthier America Calls on All Americans to Curtail Health Care Costs in 2010 by Becoming Physically Active [0] STDs Common Among Sexually Active Teen Girls in Cities [0] A World-Class HR Master's Degree Is Now Within Reach – 100% Online [0] Neurocrine Announces Sale of 4,784,689 Shares of Common Stock, to Raise Proceeds of $10 Million [0] Labopharm Initiates Regulatory Approval Process for Twice-Daily Tramadol-Acetaminophen in Europe

... AARP asks,Governor Schwarzenegger to fight on behalf ... the State Children,s Health,Insurance Program (SCHIP). The U.S. ... and extend SCHIP, covering millions of low-income,uninsured children ... to veto,any bill that would expand the program ...

... National Board of Medical,Examiners is appealing the decision ... which granted the petition of breastfeeding,mother Sophie Currier ... "Our overriding concerns are fairness to all examinees ... an important gateway to medical,practice," said Joseph F. ...

... exclusive North American rights to bepotastine for nasal ... ... 26 ISTA,Pharmaceuticals, Inc. (Nasdaq: ISTA ), announced today it ... an,investigational product for the treatment of allergy symptoms, from Tanabe,Seiyaku Co., ...

... Offers Families Information, Access to Experts and Advice on how to ... Navigate Health Care System ... Speaker, NEW YORK, Sept. 26 Nearly 10 million women,and one ... yet to be clinically identified and treated. How does,one identify an eating ...

... the fall season has,officially begun, the need to protect four-legged ... original,online home of animal health news, offers pet owners these ... -- Fleas are the most common external parasite in cats ... humid environments and feed on the blood of their ...

... to the National,Breast Cancer Foundation, nearly 200,000 women will ... lives, and while it is,widely known that a mammogram ... of women either can,t afford to receive testing or ... to mammograms for,women in underserved communities, Colgate-Palmolive (NYSE: ...

Other Medicine News:Health News:AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill 2 Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 2 Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 3 Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 4 Health News:ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments 5 Health News:Does your Child or Spouse have an Eating Disorder? If They Did, Would You Know? 2 Health News:Summer Temperatures Linger, Extend Threat of Parasites 2 Health News:Colgate-Palmolive Partners With the National Breast Cancer Foundation to Provide Education and Free Mammograms 2 Health News:Colgate-Palmolive Partners With the National Breast Cancer Foundation to Provide Education and Free Mammograms 3

AARP Calls on Governor Schwarzenegger to Discourage Veto of SCHIP Expansion Bill NBME Appeals Massachusetts Judge's Reversal of Lower Court in Suit for Extra Break Time During Medical Licensing Exam ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments Does your Child or Spouse have an Eating Disorder? If They Did, Would You Know?Summer Temperatures Linger, Extend Threat of Parasites Colgate-Palmolive Partners With the National Breast Cancer Foundation to Provide Education and Free Mammograms

All Day Comfort for the Upper Body...

Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....

The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....

This aron protects at 0.5 mm Pb equivalency and is 20% lighter than our Standard Back-Aid Apron - yet it contains no lead products that can be harmful to the environment!...

Medicine Products:

Vest Guard (Vest for Women)Wrap-Around Lead Apron Buckle Lead Apron Qualcraft™ Lead-Free Back-Aid Radiation Protection Apron

New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients wit...(taneous conversion to monotherapy from t...),Health